Curis (CRIS) Outpaces in Q3; Roth Affirms 'Buy' Rating Ahead of ASH

November 9, 2015 2:54 PM

Roth Capital reaffirms Curis (Nasdaq: CRIS) with a Buy rating and $5 price target following Q3 results and update issued ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found